Crude Ethanolic Extract, Lignoid Fraction and Yangambin from Ocotea duckei (Lauraceae) Show Antileishmanial Activity

Zeitschrift fur Naturforschung - Section C Journal of Biosciences

Volumn 62, Issue 5-6, 2007, Pages 348-352

  Monte, Rubens L ^a   Barbosa, José M ^a   Athayde, Petronio F ^a   Dias, Celidarque S ^a   Oliveira, Marcia R ^a   Sousa, Louisa M A ^a  

^a FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

Author keywords

Antileishmanial Activity; Leishmania; Ocotea duckei

Indexed keywords

ALCOHOL; ANTIPROTOZOAL AGENT; EPIYANGAMBIN; FURAN DERIVATIVE; LIGNAN; PLANT EXTRACT; UNCLASSIFIED DRUG;

ANGIOSPERM; ANIMAL; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; ISOLATION AND PURIFICATION; LEISHMANIA INFANTUM;

ANIMALS; ANTIPROTOZOAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; FURANS; LAURACEAE; LEISHMANIA INFANTUM; LIGNANS; MODELS, MOLECULAR; PLANT EXTRACTS;

BOVINAE; LAURACEAE; LEISHMANIA AMAZONENSIS; LEISHMANIA DONOVANI CHAGASI; MAGNOLIOPHYTA; OCOTEA; OCOTEA DUCKEI;

EID: 34548627345     PISSN: 09395075     EISSN: None     Source Type: Journal    
DOI: 10.1515/znc-2007-5-605     Document Type: Article

References (21)

1. Almeida R. N., Pachu C. O., and Barbosa-Filho J. M. (1995), Avaliaifäo da possivel atividade analgesica da iangambina obtida de Ocotea duckei Vattimo. Cienc. Cult. Saude 14, 7-10.
2. Araujo C. A. C., Alegrio L. V., and Leon L. L. (1998), Antileishmanial activity of compounds extracted and characterized from Centrolobium sclerophylum. Phytochemistry 49, 751-754.
3. Araujo C. V., Barbosa-Filho J. M., Cordeiro R. S., and Tibirica E. (2001), Protective effects of yangambin on cardiovascular hyporeactivity to catecholamines in rats with endotoxin-induced shock. Naunyn-Schmie-deberg's Arch. Pharmacol. 363, 267-275.
4. Barbosa-Filho J. M., Vargas M. R. W., Silva I. G., Franca I. S., Morais L. C. S. L., Cunha E. V. L., Da Silva M. S., Souza M. F. V., Chaves C. O. M., Almeida R. N., and Agra M. F. (1999), Ocotea duckei: Exceptional source of yangambin and other furofuran lignans. An. Acad. Bras. Cienc. 71, 231-238.
5. Berman J. D. (1997), Human leishmaniasis: clinical, diagnostic and chemotherapeutic developments in the last 10 years. Clin. Infec. Dis. 24, 684-703.
6. Boelaert M., Le-Ray D., and Vander S. P. (2002), How better drugs could change kala-azar control. Lessons from a cost-effectiveness analysis. Trop. Med. Int. Health 7, 955-959.
7. Brandao-Filho S. and Shaw J. (1994), Leishmaniasis in Brazil. Parasitol. Today 10, 329-330.
8. Carvalho P. B. and Ferrreira E. I. (2001), Leishmaniasis phytotherapy. Nature's leadership against an ancient disease. Fitoterapia 72, 599-618.
9. Dias C. S., Silva I. G., Cunha E. V. L., Silva M. S., and Barbosa-Filho J. M. (2003), Isolamento e identificaifäo de novos alcaloides de Ocotea duckei Vattimo (Lauraceae). Rev. Bras. Farmacogn. 13 (Suppl 1), 62-63.
10. Franca F., Lago E. L., and Marsden P. D. (1996), Plants used in treatment of leishmanial ulcers due to Leishmania (Viannia) brasiliensis in an endemic area of Bahia, Brazil. Rev. Soc. Bras. Med. Trop. 29, 229-232.
11. Herbert J. M., Castro-Faria-Neto H. C., Barbosa-Filho J. M., Cordeiro R. S. B., and Tibirica E. (1997), Pharmacological evidence for the putative existence of two different subtypes of PAF receptors on platelets and leukocytes studies with yangambin. Lipid Mediators Cell Signal 17, 1-14.
12. Lira R., Sundar S., Makharia A., Kenney R., Gam A., Saraiva E., and Sacks D. (1999), Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 180, 564-657.
13. Marques R. C. P., Medeiros S. R. B., Dias C. S., Barbosa Filho J. M., and Agnez-Lima L. F. (2003), Evaluation of the mutagenic potential of yangambin and of the hydroalcoholic extract of Ocotea duckei by the Ames test. Mutat. Res.-Gen. Tox. En. 536, 117-120.
14. Marzochi M. C. A. and Marzochi K. B. F. (1994), Tegu-mentary and visceral leishmaniasis in Brazil-Emerging anthropozoonosis and possibilities for their control. Cad. Saude Pübl. 10, 359-375.
15. Pachu C. O., Almeida R. N., and Barbosa-Filho J. M. (1993), Atividade depressora do sistema nervoso central pela iangambina. Cienc. Cult. Saude 12, 14-16.
16. Pearson R. D. and Souza A. Q. (1996), Clinical spectrum of leishmaniasis. Clin. Infect. Dis. 22, 1-11.
17. Rocha H. K. W. C., Gomes V. V., Guedes-Filho G. E., Tafuri W. L., Medeiros A. C., and Oliveira M. R. (2004), Isolation and characterization of parasites responsible for visceral leishmaniasis in Joao Pessoa-Paraiba-Brazil. Rev. Bras. Cienc. Saude 8, 15-24.
18. Rocha L. G., Almeida J. R., Macedo R. O., and Barbosa-Filho J. M. (2005), A review of natural products with antileishmanial activity. Phytomedicine 12, 514-535.
19. Rosa M. S., Mendonca-Filho R. R., Bizzo H. R., Rodrigues I. A., Soares R. M. A., Souto-Padron T., Alvi-ano C. S., and Lopes A. H. C. S. (2003), Antileishmanial activity of linalool-rich essential oil from Croton cajucara. Antimicrob. Agents Chemother. 47, 1895-1901.
20. Serra M. F., Diaz B. L., Barreto E. O., Perreira A. P. B., Lima M. C. R., Barbosa-Filho J. M., Cordeiro R. S. B., Martins M. A., and Silva P. M. R. (1997), Anti-allergic properties of the natural PAF antagonist yangambin. Planta Med. 63, 207-212.
21. World Health Organization (WHO) (2004), Special Programe for Research and Training in Tropical Diseases-TDR. Disease Information. Available in < http: //www. who. int/tdr/diseases/leish/diseaseinfo. htm >. Accessed 20/10/2004.